The deal encompasses medications including Xiidra, a treatment for dry eyes disease; SAF312, a therapy for ocular surface pain; and AcuStream.
Novartis will receive milestone payments of up to $750 million for anticipated future sales of Xiidra, SAF312 and OJL332, a TRPV1 antagonist in preclinical development, according to a June 30 press release. Novartis will continue to supply Xiidra to patients for a time on behalf of Bausch + Lomb via transitional agreements.
The deal is expected to close in the second half of 2023, subject to regulatory approval and conditions.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.